Alopecia Areata – Opportunity Analysis and Forecasts to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alopecia areata (AA) is the second most common non-scarring alopecia and there are no clear reasons for the onset of the condition; however, some sources have suggested that it happens as a result of genetic susceptibility from an environmental change. The disease causes hair loss from different areas of the body; however, it usually occurs more on the scalp or the beard regions. It appears as smooth round patches but with the follicular openings retained, where the hair has become shorter and fragmented because of the disease. Hair loss can result in baldness of the whole scalp, which is referred to as alopecia totalis, or loss of hair on the body, which is called alopecia universalis. Both genders are equally affected, with symptoms of AA starting commonly before the age of 30. The condition occurs in at least 20% of patients who have a first-degree relative who suffers from AA.

Scope

Overview of AA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized AA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AA therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global AA market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main driver of the enormous expansion of the AA market will be the significant increase in patient shares towards the JAK inhibitors due to increased efficacy of these therapies.

Another prominent contributor to sales growth will be the increase in treatment rate in all markets accross the 7MM

The major global barrier for the AA market will be the annual cost of therapy for the new pipeline drugs

The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for AA patients with less occurrence of adverse events

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global AA therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AA therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global AA therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Eli Lilly
Pfizer

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Alopecia Areata: Executive Summary

2.1 Intense Growth Expected for AA Market Following the Launch of JAK Inhibitors

2.2 Large Companies Set to Dominate the AA Market

2.3 Vast Unmet Needs Exist in the AA Market

2.4 There is Still Scope for Opportunity in AA Despite the Entrance of JAK Inhibitors

2.5 JAK Inhibitors Dominate Sales for AA

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.3 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Forecast Assumptions and Methods – Diagnosed Incident Cases of AA

5.4.4 Forecast Assumptions and Methods – Lifetime Diagnosed Prevalent Cases of AA

5.4.5 Forecast Assumptions and Methods – Diagnosed Incident Cases and Lifetime Diagnosed Prevalent Cases of AA by Severity

5.5 Epidemiological Forecast for AA (2018–2028)

5.5.1 Diagnosed Incident Cases of AA

5.5.2 Age-Specific Diagnosed Incident Cases of AA

5.5.3 Sex-Specific Diagnosed Incident Cases of AA

5.5.4 Diagnosed Incident Cases of AA by Severity

5.5.5 Lifetime Diagnosed Prevalent Cases of AA

5.5.6 Age-Specific Lifetime Diagnosed Prevalent Cases of AA

5.5.7 Sex-Specific Lifetime Diagnosed Prevalent Cases of AA

5.5.8 Lifetime Diagnosed Prevalent Cases of AA by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis

6.3 Treatment

6.3.1 Topical Treatments

6.3.2 Systemic Treatments

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Efficacious Drugs

7.3 Patient Adherence

7.4 Lack of Treatment Guidelines

7.5 Reimbursement Potential for Medications

8 R&D Strategies

8.1 Overview

8.1.1 JAK Inhibitors

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Design

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 General Pricing Assumptions

11.3.6 Individual Drug Assumptions

11.3.7 Generic Erosion

11.3.8 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.4.1 KOLs

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table

Table 1: Alopecia Areata: Key Metrics in the 7MM

Table 2: Alopecia Areata – Investigational Guidelines Assessment

Table 3: Risk Factors and Comorbidities for AA

Table 4: Clinical Trial Design for Key AA Products in Late-Stage Development, July 2019

Table 5: Innovative Early-Stage Approaches for Alopecia Areata, 2019

Table 6: Clinical Benchmark of Key Pipeline Drugs – Alopecia Areata, 2018

Table 7: Commercial Benchmark of Key Pipeline Drugs – Alopecia Areata, 2018

Table 8: Key Events Impacting Sales for AA, 2018–2028

Table 9: AA Market – Global Drivers and Barriers, 2018–2028

Table 10: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for AA in 2018 and 2028

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC),,topical immunotherapy

Figure 3: Pathogenesis of Alopecia Areata

Figure 4: Visuals for Estimating the Percentage of Scalp Hair Loss to Calculate SALT Scores

Figure 5: 7MM, Diagnosed Incidence of Alopecia Areata, Both Sexes, All Ages, 2018

Figure 6: 7MM, Lifetime Diagnosed Prevalence of Alopecia Areata, Both Sexes, All Ages, 2018

Figure 7: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Alopecia Areata

Figure 8: 7MM, Sources Used to Forecast the Lifetime Diagnosed Prevalent Cases of Alopecia Areata

Figure 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases and Lifetime Diagnosed Prevalent Cases by Severity of AA

Figure 10: 7MM, Diagnosed Incident Cases of AA, Both Sexes, All Ages, 2018

Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of AA, Both Sexes, All Ages, 2018

Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of AA, All Ages, 2018

Figure 13: 7MM, Diagnosed Incident Cases of AA by Severity, Both Sexes, All Ages, 2018

Figure 14: 7MM, Lifetime Diagnosed Prevalent Cases of AA, Both Sexes, All Ages, 2018

Figure 15: 7MM, Age-Specific Lifetime Diagnosed Prevalent Cases of AA, Both Sexes, All Ages, 2018

Figure 16: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of AA, All Ages, 2018

Figure 17: 7MM, Lifetime Diagnosed Prevalent Cases of AA by Severity, Both Sexes, All Ages, 2018

Figure 18: Treatment Paradigm for Alopecia Areata

Figure 19: Unmet Needs and Opportunities in Alopecia Areata

Figure 20: Overview of the Development Pipeline in Alopecia Areata

Figure 21: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Alopecia Areata in the 7MM During the Forecast Period

Figure 22: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, topical immunotherapy

Figure 23: Global (7MM) Sales Forecast by Country for AA in 2018 and 2028

Figure 24: Global Sales Forecast by Class for AA in 2018 and 2028

Figure 25: Sales Forecast by Class for AA in the US in 2018 and 2028

Frequently asked questions

Alopecia Areata – Opportunity Analysis and Forecasts to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Alopecia Areata – Opportunity Analysis and Forecasts to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alopecia Areata – Opportunity Analysis and Forecasts to 2028 in real time.

  • Access a live Alopecia Areata – Opportunity Analysis and Forecasts to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.